Spesolimab - Boehringer Ingelheim
Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGOLatest Information Update: 07 May 2024
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Generalised pustular psoriasis
- Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
- Phase II Crohn's disease; Palmoplantar pustulosis; Pyoderma gangrenosum
- Discontinued Atopic dermatitis
Most Recent Events
- 26 Apr 2024 Boehringer Ingelheim completes phase-II clinical trials in Hidradenitis suppurativa in Poland, Greece, USA, Canada, France, Hungary, Australia, Belgium, Czech Republic, Germany, Italy, Netherlands, Norway, Spain, Denmark. Italy, UK (SC) (IV) (NCT04876391)
- 16 Apr 2024 Phase-II/III clinical trials in Hidradenitis suppurativa (Treatment-experienced) in Canada (SC) (NCT06241573) (EudraCT2023-508377-82-00)
- 19 Mar 2024 Launched for Generalised pustular psoriasis (In adolescents, In children) in USA (IV)